Dr. Kim on the Role of Biomarker Testing in Treatment Decisions for Solid Tumors

Publication
Video
Supplements And Featured PublicationsOn the Horizon in NSCLC: Antibody Drug Conjugates

Edward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

Edward S. Kim, MD, MBA, physician-in-chief at City of Hope Orange County and vice physician-in-chief at City of Hope National Medical Center, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

With the emergence of targeted therapies and different agents for the treatment of various malignancies, biomarker testing has become an essential part of the diagnosis of a patient, Kim says. Although radiologic tests, pathology, and histology information are available, the full scope of the patient’s disease is not complete without biomarker testing, Kim stresses.

Despite the importance of biomarker testing, rates of testing remain significantly short of where they should be, Kim continues, adding that mutations or other biomarkers can influence treatment decisions. Biomarker testing can identify patients who may be candidates for a specific therapy that can improve their outcome or deliver similar efficacy with a better safety profile, Kim concludes.

Related Videos
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center
Muhamad Alhaj Moustafa, MD, MS, hematologist, medical oncologist, Departments of Hematology and Oncology (Medical), Mayo Clinic
Reshma Jagsi, MD, DPhil, Emory University
Chandler H. Park, MD, FACP, Norton Health
Salman R. Punekar, MD, Mayo Clinic